Retrospective Study of Implants With Peri-implantitis Surgically Treated Using Enamel Matrix Derivative (EMD)

N/ACompletedNCT05419102

North Dallas Dental Health34 enrolled

Overview

The existing records of a private practice limited to the practice of periodontology were reviewed to locate patients who had been diagnosed with peri-implantitis (failing dental implant) and had been surgically treated utilizing enamel matrix derivative (Commercially available FDA product Emdogain sold by Straumann USA). Various clinical factors were gathered from the existing records. Some of the factors recorded were: retention of the implant, presence of bleeding, presence of further damage, and presence of inflammation. All patients had signed an informed consent for treatment and the anonymous use of their data for research purposes. All HIPA requirements were followed.

See brief summary.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Determination of Beneficial Effect of Using Enamel Matrix Derivative During Implant Treatment

Interventions

peri-implantitis surgery with enamel matrix derivativePROCEDURE

Eligibility

Sex: ALLMin age: 18 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * all adult patients of record who presented with existing peri-implantitis that was clinically deemed treatable (the implant was not considered hopeless.) Exclusion Criteria: * none except for routine medical contraindications for periodontal surgery

Outcomes

Primary Outcomes

retention of the implant

Determine if the implant was still present at the time of reevaluation

Time frame: 0.71 to 6.4 years

Secondary Outcomes

record the clinical condition of the implant at the time of reevaluation

Multiple standard measurements of the clinical condition of the implant were recorded at the time of reevaluation